Hepatitis B and C seroprevalence in solid tumors - necessity for screening during chemotherapy
| Autor: | Dilek Unal, Arzu Oguz, Samet Karahan, Ahmet Karaman, Emine Uslu, Fatma Aykas, Mustafa Basak |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Hepatitis B virus Epidemiology lamuvidine medicine.medical_treatment Hepacivirus Malignancy Gastroenterology Liver Function Tests Seroepidemiologic Studies Internal medicine Neoplasms medicine Seroprevalence Humans Hepatitis B Antibodies Retrospective Studies Hepatitis Chemotherapy Hepatitis B Surface Antigens medicine.diagnostic_test business.industry Public Health Environmental and Occupational Health virus diseases Hepatitis C Hepatitis B Middle Aged medicine.disease digestive system diseases Oncology Lamivudine Immunology DNA Viral RNA Viral Female business Liver function tests Adjuvant malignancy |
| Zdroj: | Asian Pacific journal of cancer prevention : APJCP. 15(3) |
| ISSN: | 2476-762X |
| Popis: | Background: Hepatitis B and C are the leading causes of liver diseases worldwide. For hematological and solid malignancy patients undergoing chemotherapy, increases in HBV DNA and HCV RNA levels can be detected which may result in reactivation and hepatitis-related morbidity and mortality. The aim of this study was to determine the seroprevalence of Hbs ag and Anti HCV positivity in patients with solid malignancies undergoing chemotherapy and consequences during follow-up. Materials and Methods: The files of 914 patients with solid malignancies whose hepatitis markers were determined serologically at diagnosis were reviewed retrospectively. All underwent adjuvant/palliative chemotherapy. For the cases with HBV and/or HCV positivity, HBV DNA and HCV RNA levels, liver function tests at diagnosis and during follow-up and the treatment modalities that were chosen were determined. Results: Of 914 cases, Hbs Ag, anti Hbs and anti HCV positivity were detected in 40 (4.4%), 336 (36.8%) and 26 (2.8%) of the cases respectively. All of the Hbs ag positive patients received prophylactic lamuvidine before the start of chemotherapy. In the Hbs ag and anti HCV positive cases, liver failure was not detected during chemotherapy and a delay in chemotherapy courses because of hepatitis was not encountered. Conclusions: Just as with hematological malignancies, screening for HBV and HCV should also be considered for patients with solid tumors undergoing chemotherapy. Prophylactic antiviral therapy for HBV reduces both the reactivation rates and HBV related mortality and morbidity. The clinical impact of HCV infection on patients undergoing chemotherapy is still not well characterized. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|